Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating Costs and Expenses:
General and administrative	$ 7,467	$ 10,143	$ 8,074
Research and development	18,784	29,109	32,906
Total Operating Costs and Expenses	26,251	39,252	40,980
Loss from Operations	(26,251)	(39,252)	(40,980)
Other Income (Expense):
Change in fair value of warrant liability	10,738	11,412	(3,811)
Interest income	21	37	6
Total Other Income (Expense)	10,759	11,449	(3,805)
Net Loss	(15,492)	(27,803)	(44,785)
Net Loss Attributable to Non-controlling Interest	(318)	(548)	(1,048)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	(15,174)	(27,255)	(43,737)
Series A Preferred Stock Dividends	(6,962)	0	0
Net Loss Attributable to Common Stockholders	$ (22,136)	$ (27,255)	$ (43,737)
Net Loss Per Share - Basic and Dilutive	$ (0.18)	$ (0.29)	$ (0.54)
Weighted average number of shares outstanding during the period - Basic and Dilutive	124,366,059	94,290,436	80,705,692